Viatris Views Ophthalmology, Dermatology, and Gastroenterology as Future Pipeline Focus

Equity Analyst

Keonhee Kim

Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris is one of the largest generic drug manufacturers in the world. Viatris' generics business makes up roughly 40% of company's sales and, along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin 

headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. 

Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Viatris. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

The remaining 60% of Viatris’ sales is derived from off-patent branded drugs, including Lipitor, Lyrica, and Norvasc. While macrotrends like the aging population and growing emerging markets can continue to boost sales, we still expect low- to mid-single-digit erosion in the business from pricing and volume headwinds driven from more patients opting generic versions. To combat this, Viatris has identified ophthalmology, dermatology, and gastroenterology as three key therapeutic areas of focus for future innovations. Since these areas are all specialty-driven, a small salesforce can capture a large number of doctors. And a lot of innovations usually come from smaller players, meaning there is not one big leader that Viatris has to displace to gain shares. It launched Tyrvaya, the first and only nasal spray 

for the treatment of dry eye disease at the time of launch, and it expects additional products for dry eye disease going forward. In 2023, it acquired Oyster Point and Famy Life Sciences, two companies that focus on ophthalmology, and we expect additional small tuck-in acquisitions in the three therapeutic areas to fuel its pipeline.

Business Strategy & Outlook

We assign Viatris a no-moat rating because we do not believe the company possesses any structural advantages strong enough to earn excess returns and generate return on invested capital above its cost of capital over the next 10 years. 

While generic drugs were around in the U.S. since the early 20th century, their industry experienced a significant growth following the passage of the 1984 Hatch-Waxman Act. The legislation facilitated the drug application process for generic drug manufacturers by providing them a safe harbor from patent infringement litigation from branded drug manufacturers and allowed the U.S. Food and Drug Administration to approve applications for generic drugs with abbreviated new drug applications. An ANDA requires the applicant to demonstrate its generic drug’s pharmaceutical equivalence and bioequivalence to the reference drug, but it generally does not require preclinical and clinical data to prove safety and effectiveness since it relies on the FDA’s prior approval of the reference drug’s safety and effectiveness. Overall, this legislation paved a much swifter way for generics manufacturers to get their drugs approved compared with a new drug application, which a new branded drug must go through.

The U.S. generic drug industry enjoyed another boost when Congress enacted a series of amendments named the Generic Drug User Fee Amendments (first one passed in 2012, second in 2017 and the latest in 2022), allowing the FDA to collect fees from ANDA applicants to expedite application approval process. The fees (an ANDA fee rate for 2023 was around $240,000) are not meaningful to sway big generic manufacturers away and they also provide additional revenue streams and financial support to the FDA, allowing applications to be approved more quickly and efficiently. 

These regulatory pushes by the U.S. government paved ways for the industry to be highly competitive and be filled with commoditized products, eroding a lot of pricing power that generics manufacturers once had. And although there are a few number of players that make up a relatively healthy share of the generics market, barriers to entry here is quite low, expanding possibilities for firms in the space to face additional competition going forward. This explains the hike in generic dispensing rate (percentage of prescriptions dispensed with a generic rather than a branded reference drug) which grew from 54% to 91% between 2002 and 2019. And while an average of less than 300 ANDAs were approved annually from 1985 to 2012, thanks to these changes, the FDA has averaged around 1,000 ANDA approvals per year over the last five years. 

Beyond government actions, generics manufacturers also face pressures from players within the drug supply chain. The formation of powerful generic sourcing groups and establishment of generic formularies by pharmacy benefit manager enabled drug distributors and drug buyers to effectively negotiate lower generic prices, hurting manufacturers’ margins.

Three large generic sourcing programs that were formed as joint ventures between large wholesalers and drug purchasers—ClarusONE (2016, McKesson and Walmart); Red Oak Sourcing (2013, Cardinal Health and CVS); and Walgreens Boots Alliance Development (2012, AmerisourceBergen and Walgreens)—have acted as additional headwind for generics manufacturers. These entities were created to lower generics acquisition costs through the aggregation of purchasing power and as a result, they can demand higher buy-side discounts and rebates from generics manufacturers, ultimately eating into their profits. They now purchase roughly 80% of all generics sold in the U.S. Additionally, the interchangeability between generics has facilitated the establishment of generic formularies, in which wholesalers can use their purchasing scale to negotiate deeper concessions for placement in the generic sourcing program. As these three players continue to make up a larger portion of generic sourcing in the country and enhance their buying power, generics manufacturers are left with no other choice but to face the burden, resulting in low- to mid-single-digit price erosion in the market year over year.

By our estimate, roughly 40% and 50% of Viatris total sales are derived from generics and off-patent branded drugs, respectively, and both areas are highly susceptible to all the pricing headwinds mentioned above. Viatris has decided to combat this by rationalizing and optimizing its portfolio, carefully deciding which drugs to continue commercializing and which drugs to discontinue. The company opted to exit spaces where it had too many existing players and discontinue small-molecule drugs that are fairly simple to be FDA-approved and to be replicated. Furthermore, Viatris has continued to pursue more opportunities into branded drugs, aiming to launch sizable novel drugs that can have a meaningful impact on the top and bottom lines. Viatris has also sought to expand its presence in complex generics. These drugs typically face limited competition due to a more complicated level of research and development required before reaching commercial stage. Instead of being available in simple oral tablets, which are relatively easy to replicate by competitors, complex generics and biosimilars usually come in injectables, inhalers, and other different forms that pose more challenges to other manufacturers to produce. 

Despite these efforts, we don’t believe Viatris has any structural advantages over other generic manufacturers. It doesn’t have a meaningfully larger number of first-to-file launches compared with other players in the space. And even if it launches a few drugs that are first to market and gain 180-day exclusivity periods in certain products, they are likely to face direct competition as soon as that period expires, leading to significant volume reductions. If Viatris continues to downsize its portfolio of commoditized and easy-to-replicate generic drugs and replace them with more innovative medicines, we could potentially revisit our analysis. For now, we do not believe Viatris earns a moat rating.

None

Economic Moat

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc.: Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022. Additionally, Viatris announced that it was seeking to divest additional business assets and undertaking a significant global reshaping of its business, which would focus on developing products in three core therapeutic areas: ophthalmology, gastrointestinal and dermatology.

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of an Investigation and Potential Class Action Lawsuit - (NasdaqGS: VTRS)

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris Inc. (NASDAQ:VTRS ) Q1 2023 Results Conference Call May 8, 2023 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Incoming Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Glenn Santangelo - Jefferies Chris Schott - JPMorgan Balaji Prasad - Barclays David Amsellem - Piper Sandler Ash Verma - UBS Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Group Operator Good morning. My name is Gretchen, and I will be your conference operator today.

Viatris Inc. (VTRS) Q1 2023 Earnings Call Transcript

Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.93 per share a year ago.

Viatris (VTRS) Tops Q1 Earnings Estimates

Alvotech SA

Fuji Pharma Co., Ltd. is mainly a generics pharma company focused on the less volatile Japanese generics market, whose market structure is associated with less regulatory risks, competition, and generics profitability risks. Its generics focus is a positive thing in Japan since regulators want a greater generics to share in healthcare expenditure, and its products for women are low-penetration and received recent government support.

Fuji Pharma: High Scope For Growth In U.S. Foray, Biosimilars, And Women's Health Drugs

Reports Total Revenues of $3.73 billion; U.S. GAAP Net Earnings of $225 million; Adjusted EBITDA of $1.34 billion; U.S. GAAP Net Cash Provided by Operating Activities of $971 million; and Free Cash Flow of $923 million for the Quarter Expects Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow to be at Midpoint of 2023 Guidance Ranges[1] Reaffirms 2024 Phase 2 Outlook from November 7 Strategic Update Returns Approximately $400 million of Capital to Shareholders in First Quarter Through Dividends and Share Repurchases Pays Down Debt of $546 million in First Quarter Board of Directors Declares Quarterly Dividend of $0.12 per Share PITTSBURGH , May 8, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024. Executive Commentary Viatris CEO Scott A.

Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

NEW YORK , April 28, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris" or the "Company") (NasdaqGS: VTRS) concerning possible violations of federal securities laws.   Before the market opened on February 28, 2022, Viatris unexpectedly announced the Company had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022.

VTRS INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Viatris Inc.

AT&T

Viatris' business didn't grow at all last year, but the company's free cash flow is strong enough to support (and boost) its dividend payments. AT&T is coming off a tough quarter that spooked investors, but the telecom continues to expand, making it an underrated dividend stock.

Want to Collect $1,100 in Dividends? Invest $20,000 in These 2 Stocks

Agilon Health

Cano Health

Humana

Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).

4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates

Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) PITTSBURGH , April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston taking place April 22-27. Data will include results from the pivotal Phase III clinical trial exploring the efficacy and safety of GA Depot – a long-acting glatiramer acetate being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).

Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting

Abbott Labs

Cigna

Elevance Health Inc

Laboratory

Organon & Co

Pfizer

UnitedHealth Group

Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.

8 Defensive Plays as Healthcare Stocks Stumble

Centene

Continued Medicaid expansion bodes well for Centene. Viatris' drug pipeline should deliver modest growth in the years ahead.

Wall Street Thinks These 2 Value Stocks Could Soar

Teva Pharmaceutical

In theory, the stock of companies that make generic drugs have the potential to be safe investments. Despite that, companies like Teva Pharmaceuticals aren't actually safe at all.

1 "Safe" Stock to Avoid and 1 to Consider Buying in April

PITTSBURGH , April 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets. Chief Executive Officer  Scott Smith , President  Rajiv Malik , and Chief Financial Officer  Sanjeev Narula  also will host a webcast at 8:30 a.m.

Viatris to Report First Quarter 2023 Financial Results on May 8, 2023

Innovative online education platform helping global healthcare professionals address non-communicable diseases PITTSBURGH and WASHINGTON , April 6, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and the American College of Cardiology (ACC) today released the latest NCD Academy course, Health Equity and Social Determinants of Health in NCDs, coinciding with World Health Day and the theme "Health for All." The NCD Academy is a user-friendly, interactive online platform developed by the ACC in partnership with the NCD Alliance and the World Heart Federation and sponsored by Viatris.

NCD Academy Launches New Health Equity and Social Determinants of Health Course

TC Energy

AT&T, TC Energy, and Viatris are three high-yielding dividend stocks that can diversify your portfolio. The lowest payout on this list is 5% -- nearly three times the S&P 500's dividend yield.

Here's How You Can Collect $100 in Dividends Every Month

APA Corporation

Academy Sports and Outdoors

Cross Country Healthcare

Hudson Technologies

Nexstar Media Group

Encore Wire

Given the high concentration of tech and other types of growth plays trading on the Nasdaq exchange, it's easy to conflate the term “Nasdaq stocks” with growth stocks. However, there are in actuality scores of undervalued Nasdaq stocks—And not just in the sense of “relative value.

The 7 Most Undervalued Nasdaq Stocks to Buy in April 2023

All Pending Claims Have Been Dismissed PITTSBURGH , March 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) announced that the U.S. District Court for the Southern District of New York has dismissed all claims against the Company in their entirety and granted its motion for summary judgment in the securities class action related to the Company's marketing, pricing, and classification of EpiPen, as well as alleged conduct concerning generic drug price fixing and market allocation. The decision addressed all pending claims against all defendants.

Viatris Wins Summary Judgment in New York Securities Class Action

Apple

Viatris isn't growing quickly, but its dividend yield is high at the moment. Apple is growing steadily, and it has a long history of paying out to shareholders.

Which Is the Better Dividend Stock: Viatris or Apple?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

Why Is Viatris (VTRS) Down 16.4% Since Last Earnings Report?

TEGNA

Thor Industries

In stock investing, these are called value traps. Value traps are equities that appear to be inexpensive because they have low valuations.

Don't Be Fooled by These 3 Value Traps

To say Viatris has been a sore disappointment since its spin-off, would be a massive understatement. The company came into its listing on very low valuations and had to do very little right to deliver average returns.

Viatris: The Value And The Value Trap

Embecta Corp

GE HealthCare Technologies Inc

Embecta should benefit from the greater need for diabetic services. Viatris is focusing on finding new generics.

3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential

AbbVie

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

DoubleLine Yield Opportunities Fund

Devon Energy

Enterprise Products Partners

Innovative Industrial Properties

Medical Properties Trust

ONEOK

Williams

The group of 12 high-yielders consists of pharma stocks, oil and gas stocks, REITs, and more. Several of them face higher risks than others.

I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.

News for Viatris Stock (VTRS)